iSpecimen Inc

Company Profile

iSpecimen Inc had its IPO on 2021-06-17 under the ticker symbol ISPC.

The company operates in the Healthcare sector and Diagnostics & Research industry. iSpecimen Inc has a staff strength of 75 employees.

Stock update

Shares of iSpecimen Inc opened at $0.7 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.62 - $0.7, and closed at $0.65.

This is a -3.96% slip from the previous day's closing price.

A total volume of 32,199 shares were traded at the close of the day’s session.

In the last one week, shares of iSpecimen Inc have slipped by -8.14%.

iSpecimen Inc's Key Ratios

iSpecimen Inc has a market cap of $6.45 million, indicating a price to book ratio of 0.5477 and a price to sales ratio of 1.2278.

In the last 12-months iSpecimen Inc’s revenue was $10.12 million with a gross profit of $5.65 million and an EBITDA of $-11257905. The EBITDA ratio measures iSpecimen Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, iSpecimen Inc’s operating margin was -112.12% while its return on assets stood at -29.57% with a return of equity of -55.84%.

In Q2, iSpecimen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 30.5%.

iSpecimen Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into iSpecimen Inc’s profitability.

iSpecimen Inc stock is trading at a EV to sales ratio of 0.0155 and a EV to EBITDA ratio of 0.5326. Its price to sales ratio in the trailing 12-months stood at 1.2278.

iSpecimen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$17.57 million

Total Liabilities

$2.86 million

Operating Cash Flow

$0

Capital Expenditure

$1.20 million

Dividend Payout Ratio

0%

iSpecimen Inc ended 2024 with $17.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.57 million while shareholder equity stood at $14.71 million.

iSpecimen Inc ended 2024 with $0 in deferred long-term liabilities, $2.86 million in other current liabilities, 906.00 in common stock, $-54180750.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.00 million and cash and short-term investments were $8.21 million. The company’s total short-term debt was $107,975 while long-term debt stood at $0.

iSpecimen Inc’s total current assets stands at $10.97 million while long-term investments were $0 and short-term investments were $6.21 million. Its net receivables were $2.57 million compared to accounts payable of $1.78 million and inventory worth $0.

In 2024, iSpecimen Inc's operating cash flow was $0 while its capital expenditure stood at $1.20 million.

Comparatively, iSpecimen Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.65

52-Week High

$2.58

52-Week Low

$0.611

Analyst Target Price

$5

iSpecimen Inc stock is currently trading at $0.65 per share. It touched a 52-week high of $2.58 and a 52-week low of $2.58. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $1.21 and 200-day moving average was $1.41 The short ratio stood at 0.69 indicating a short percent outstanding of 0%.

Around 4155.2% of the company’s stock are held by insiders while 591.7% are held by institutions.